Key facts
- This page summarizes Scott Requadt's Form 4 filing for Talaris Therapeutics, Inc. (TRML).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2023, 17:19.
Scott Requadt - 03 Jul 2023 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)
- Reporting relationship
- Former Chief Executive Officer
- Issuer ticker
- TRML
- Reported as of
- 03 Jul 2023
- Net transaction value
- -$36,301
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2023, 17:19:16 UTC
- Prior SEC filing
- 03 Feb 2023
- Next SEC filing
- 16 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Kay Fenton, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott Requadt filed Form 4 for Talaris Therapeutics, Inc. (TRML) on 06 Jul 2023.
Change
- Previous filing in this sequence was filed on 03 Feb 2023.
- Current net transaction value: -$36,301.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TALS
transaction
Common Stock
Tax liability
- Transaction value
- $36,301
- Shares
- -11,786
- Change %
- -2%
- Price
- $3.08
- Shares after
- 578,403
- Date
- 03 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
TALS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 449,766
- Date
- 03 Jul 2023
- Ownership
- See footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023.
Footnote F2
These shares are held by Requadt Family Limited Partnership. The reporting person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.